Health Screening and Promotion Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
J Crohns Colitis. 2015 Nov;9(11):1053-7. doi: 10.1093/ecco-jcc/jjv135. Epub 2015 Jul 27.
Limited data are available regarding the pulmonary toxicity of anti-tumour necrosis factor (anti-TNF) therapy for inflammatory bowel disease (IBD).
We retrospectively searched the IBD registry of Asan Medical Center in order to identify patients with lung injury following anti-TNF therapy.
Among 1002 patients who were treated using anti-TNF therapy, six cases (0.6%) of anti-TNF-induced lung injury (ATILI) were identified. ATILI was observed soon after the beginning of anti-TNF therapy (two to four doses of anti-TNF). All of these patients experienced improvements in their respiratory symptoms and radiographic findings once the anti-TNF therapy was discontinued. One patient who suffered ATILI following adalimumab was switched to subsequent infliximab and was without recurrence of ATILI.
Clinicians should be vigilant regarding the possibility of ATILI in IBD patients treated with anti-TNF agents.
关于抗肿瘤坏死因子（anti-TNF）治疗炎症性肠病（IBD）的肺毒性，目前的数据有限。
我们回顾性地检索了 Asan 医疗中心的 IBD 登记处，以确定接受抗 TNF 治疗后发生肺损伤的患者。
在接受抗 TNF 治疗的 1002 例患者中，发现 6 例（0.6%）抗 TNF 诱导的肺损伤（ATILI）。ATILI 在抗 TNF 治疗开始后不久（使用抗 TNF 治疗两到四剂时）出现。一旦停止抗 TNF 治疗，所有这些患者的呼吸症状和影像学发现均有所改善。一名在阿达木单抗治疗后发生 ATILI 的患者随后改用英夫利昔单抗，且未再发生 ATILI。
对于接受抗 TNF 药物治疗的 IBD 患者，临床医生应警惕 ATILI 的可能性。
